Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Rede Goiana de Pesquisa em Tuberculose, Goiânia, GO, Brasil.
Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Mem Inst Oswaldo Cruz. 2024 Oct 4;119:e240093. doi: 10.1590/0074-02760240093. eCollection 2024.
Tuberculosis (TB) continues to be the world's leading killer of infectious diseases. Despite global efforts to gradually reduce the number of annual deaths and the incidence of this disease, the coronavirus disease 19 (COVID-19) pandemic caused decreased in TB detection and affected the prompt treatment TB which led to a setback to the 2019 rates. However, the development and testing of new TB vaccines has not stopped and now presents the possibility of implanting in the next five years a new vaccine that is affordable and might be used in the various key vulnerable populations affected by TB. Then, this assay aimed to discuss the main vaccines developed against TB that shortly could be selected and used worldwide, and additionally, evidence the Brazilian potential candidates' vaccines in developing in Brazil that could be considered among those in level advanced to TB end.
结核病（TB）仍然是全球头号传染病杀手。尽管全球一直在努力逐步减少每年的死亡人数和该病的发病率，但 2019 冠状病毒病（COVID-19）大流行导致结核病检测减少，并影响了及时治疗结核病，导致 2019 年的发病率出现倒退。然而，新的结核病疫苗的开发和测试并没有停止，现在有可能在未来五年内引入一种新的、负担得起的疫苗，可能用于受结核病影响的各种关键弱势群体。因此，本研究旨在讨论短期内可能在全球范围内选择和使用的针对结核病的主要疫苗，并进一步探讨巴西在开发新疫苗方面的潜力，这些疫苗可能被认为处于结核病防治的高级阶段。
